Strong income was not enough to please Conformis, Inc. (NASDAQ: CFMS) over the past week. Our analysis revealed several factors of concern in the earnings report, beyond the high number of statutory benefits.
Check out our latest review for Conformis
Examination of the cash flow against the profits of Conformis
A key financial ratio used to measure how well a business converts earnings into free cash flow (FCF) is the accumulation rate. The accrual ratio subtracts the FCF from the profit for a given period and divides the profit by the average operating assets of the company over that period. The ratio shows us by how much a company’s profit exceeds its FCF.
Therefore, a negative accumulation ratio is positive for the company and a positive accumulation ratio is negative. While having an accumulation ratio greater than zero is of little concern, we believe it is worth noting when a company has a relatively high accumulation ratio. Notably, some academic evidence suggests that a high accrual ratio is a bad sign for short-term profits, in general.
Comply with an accrual ratio of 0.96 for the year through June 2021. Generally, this does not bode well for future profitability. Namely, the company did not generate any free cash flow during this period. In the past twelve months he had in fact negative free cash flow, with an outflow of US $ 12 million despite its profit of US $ 13.7 million mentioned above. We also note that Conformis’ free cash flow was actually negative last year as well, so we were able to understand if shareholders were embarrassed by its outflow of $ 12 million. Notably, the company issued new shares, thereby diluting existing shareholders and reducing their share of future earnings. The good news for shareholders is that Conformis’ accumulation ratio was much better last year, so this year’s misreading could simply be a case of a short-term mismatch between earnings and FCF. Shareholders should seek an improvement in cash flow relative to current year earnings, if this is indeed the case.
This might make you wonder what analysts are predicting in terms of future profitability. Fortunately, you can click here to see an interactive graph depicting future profitability, based on their estimates.
One of the essential aspects of assessing earnings quality is to determine the extent to which a company dilutes its shareholders. In fact, Conformis has increased the number of shares issued by 140% over the past twelve months by issuing new shares. This means that its profits are distributed among a greater number of stocks. Talking about bottom line without noticing earnings per share is getting distracted by the big numbers while ignoring the smaller numbers that speak to you. per share value. You can see a graph of Conformis’ EPS by clicking here.
A look at the impact of the dilution of Conformis on its earnings per share (EPS).
Three years ago, Conformis lost money. Zooming in on last year, we still can’t talk about growth rate consistently, since it made a loss last year. But math aside, it’s always good to see when a once unprofitable business comes to fruition (although we accept that the profit would have been higher if dilution hadn’t been necessary). And so, you can see quite clearly that dilution has a pretty big impact on shareholders.
In the long term, if the benefits of Conformis per share may rise, so should the share price. But on the other hand, we would be a lot less excited to hear that earnings (but not EPS) were improving. For the ordinary retail shareholder, EPS is an excellent metric for checking your hypothetical “share” of the company’s earnings.
Our perspective on Conformis’ earnings performance
In conclusion, Conformis has low cash flow to earnings which indicates lower quality earnings, and dilution means shareholders now own a smaller proportion of the company (assuming they keep the same number actions). On reflection, the factors mentioned above give us the strong impression that the underlying profit power of Conformis is not as good as it looks, based on the statutory profit figures. So while the quality of the benefits is important, it is just as important to take into account the risks that Conformis is currently facing. For example, Conformis a 5 warning signs (and 3 that are a bit rude) you should know about.
In this article, we’ve looked at a number of factors that can undermine the usefulness of profit numbers, and we’ve come out of it cautiously. But there are plenty of other ways to tell your opinion about a business. For example, many people see a high return on equity as an indication of a favorable business economy, while others like to “follow the money” and look for stocks that insiders are buying. Although it may take a bit of research on your behalf, you can find this free set of companies offering a high return on equity, or that list of stocks that insiders buy to be useful.
If you decide to trade Conformis, use the cheapest platform * which is ranked # 1 overall by Barron’s, Interactive Brokers. Trade stocks, options, futures, currencies, bonds and funds in 135 markets, all from one integrated account.
This Simply Wall St article is general in nature. We provide commentary based on historical data and analyst forecasts using only unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell shares and does not take into account your goals or your financial situation. Our aim is to bring you long-term, targeted analysis based on fundamental data. Note that our analysis may not take into account the latest announcements from price sensitive companies or qualitative documents. Simply Wall St has no position in any of the stocks mentioned.
*Interactive Brokers Ranked Least Expensive Broker By StockBrokers.com Online Annual Review 2020
Do you have any feedback on this item? Are you worried about the content? Enter into a contract with us directly. You can also send an email to the editorial team (at) simplywallst.com.